June 23, 2017 / 2:33 PM / 3 months ago

BRIEF-Syros announces preclinical data on SY-1425

June 23 (Reuters) - Syros Pharmaceuticals Inc :

* Syros presents data at EHA supporting potential of SY-1425, its first-in-class selective RARα agonist, in genomically defined AML and MDS patients

* Preclinical data demonstrate synergistic activity of SY-1425 with standard-of-care AML and MDS therapies and anti-CD38 therapies Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below